OCUL
NASDAQ
$8.71
Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $27.09 (+211.02%)
Market Cap
$2.18B
FCF 5Y CAGR
+35.47%
Free Cash Flow Yield
-11.05%
Beta (5Y)
1.29
Price Chart
Valuation
Market Cap$2.18B
P/S40.81
P/B3.73
Profitability
Total Revenue (TTM)$52M
Gross Profit (TTM)-$175M
EBITDA-$295M
Operating Margin-865%
EPS-$1.49
Financial Health
Free Cash Flow Yield-11.05%
Growth & Risk
EPS 5Y CAGR-4.26%
Revenue 5Y CAGR+18.64%
FCF 5Y CAGR+35.47%
Beta (5Y)1.29
Sharpe Ratio-0.10